These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 21691580)
1. Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm. Park J; Lee MS; Harrison AR Clin Ophthalmol; 2011; 5():725-32. PubMed ID: 21691580 [TBL] [Abstract][Full Text] [Related]
2. A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins. Jimenez-Shahed J Neuropsychiatr Dis Treat; 2012; 8():13-25. PubMed ID: 22275842 [TBL] [Abstract][Full Text] [Related]
3. A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin®: a new botulinum neurotoxin A. Pagan FL; Harrison A Parkinsonism Relat Disord; 2012 Jun; 18(5):441-5. PubMed ID: 22405829 [TBL] [Abstract][Full Text] [Related]
4. Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects. Mitsikostas DD; Dekundy A; Hanschmann A; Althaus M; Scheschonka A; Pagan F; Jankovic J Curr Med Res Opin; 2021 Oct; 37(10):1761-1768. PubMed ID: 34384301 [TBL] [Abstract][Full Text] [Related]
5. Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®. Frevert J Drugs R D; 2010; 10(2):67-73. PubMed ID: 20698714 [TBL] [Abstract][Full Text] [Related]
6. A direct comparison of onabotulinumtoxina (Botox) and IncobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm: a split-face technique. Saad J; Gourdeau A J Neuroophthalmol; 2014 Sep; 34(3):233-6. PubMed ID: 24739994 [TBL] [Abstract][Full Text] [Related]
7. AbobotulinumtoxinA (Dysport Field M; Splevins A; Picaut P; van der Schans M; Langenberg J; Noort D; Snyder D; Foster K Toxins (Basel); 2018 Dec; 10(12):. PubMed ID: 30551641 [TBL] [Abstract][Full Text] [Related]
8. Five-year experience with incobotulinumtoxinA (Xeomin(®) ): the first botulinum toxin drug free of complexing proteins. Dressler D Eur J Neurol; 2012 Mar; 19(3):385-9. PubMed ID: 22035051 [TBL] [Abstract][Full Text] [Related]
9. Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines. Prager W Clin Pharmacol; 2013; 5():39-52. PubMed ID: 23516136 [TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm. Jankovic J Eur J Neurol; 2009 Dec; 16 Suppl 2():14-8. PubMed ID: 20002742 [TBL] [Abstract][Full Text] [Related]
11. Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders. Jost WH; Benecke R; Hauschke D; Jankovic J; Kaňovský P; Roggenkämper P; Simpson DM; Comella CL Drug Des Devel Ther; 2015; 9():1913-26. PubMed ID: 25897202 [TBL] [Abstract][Full Text] [Related]